Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EQL Pharma AB ( (SE:EQL) ) has provided an announcement.
EQL Pharma AB has appointed its Nomination Committee for the 2026 Annual General Meeting, following its standard process of selecting representatives from the three largest shareholders by voting power. The committee will comprise Christer Fåhraeus, representing Fårö Capital AB, Rajiv I Modi from Cadila Pharmaceuticals Ltd., and Sten Irwe, ahead of the AGM scheduled in Lund on 20 August 2026.
The Nomination Committee is tasked with preparing proposals on board composition, board and committee remuneration, auditor election and fees, and the principles governing future nomination processes. This governance step signals continuity in EQL Pharma’s ownership influence and board oversight as the company advances its portfolio of niche generics in the Nordic and European pharmaceutical markets.
More about EQL Pharma AB
EQL Pharma AB is a Lund-based pharmaceutical company specializing in the development and sale of niche generic prescription medicines, including hospital products. The firm focuses on the Nordic region and selected European markets, with more than 47 approved niche generics and a substantial pipeline for future launches, and it collaborates with contract manufacturers and pharmaceutical partners in the EU and Asia.
Average Trading Volume: 30,349
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.96B
Find detailed analytics on EQL stock on TipRanks’ Stock Analysis page.